Todas las investigaciones
ReclutamientoExploratorio terapéutico (Fase II)Intervencionista

Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RADIOLA TRIAL

This study, called RADIOLA, is looking at a medicine called Lynparza (which comes as tablets) for people with advanced HER2-negative breast cancer that has spread or can't be removed by surgery. This includes both triple-negative breast cancer and hormone-positive breast cancer that hasn't responded to other treatments. Researchers want to see how effective Lynparza is at shrinking tumours in people who have certain genetic changes (in genes like BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, or a specific test called 'RAD51-foci low'). By understanding this, the study aims to find out if Lynparza could be a helpful treatment for these particular groups of patients, offering a new possible way to fight their cancer.

De un vistazo

Estado
Reclutamiento
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Solti Group
Objetivo de inscripción
63
Inicio
03 Jun 2024

¿De qué trata este estudio?

This study, known as the RADIOLA Trial, is exploring a new way to treat certain types of advanced breast cancer. Specifically, it's for people with HER2-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery (locally advanced). This includes two main groups: those with triple-negative breast cancer, and those with hormone receptor-positive breast cancer that hasn't responded to previous hormone therapy with CDK4/6 inhibitors.

The main goal of the study is to see how well a drug called Lynparza works in these patients. Lynparza is a tablet medicine already used for some types of cancer. The researchers are especially interested in whether Lynparza is effective for patients who have specific changes in their genes, such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, or who have a particular test result showing 'RAD51-foci low' in their tumour cells. These gene changes might make cancer cells more sensitive to Lynparza.

By carefully watching how patients respond to Lynparza, the study aims to understand if this medicine can shrink tumours in these specific groups of people. This understanding is very important because it could help doctors choose the best treatments for patients based on the unique features of their cancer. This is a "Phase II" study, which means it builds on earlier research and aims to confirm how well a treatment works and its safety in a larger group of patients. The results will help guide future treatment decisions.

Puntos clave

  • The study is testing Lynparza for advanced HER2-negative breast cancer.
  • It's for people with specific gene changes (like BRCA1/2) or a 'RAD51-foci low' test.
  • The main goal is to see how well Lynparza shrinks tumours in these patients.
  • It's a Phase II study, meaning it checks effectiveness and safety.
  • Participation involves taking tablets and having regular check-ups and scans.

¿Quién puede ser elegible?

To be considered for this study, you must be an adult (18 years or older), male or female, and have been diagnosed with advanced breast cancer that is HER2-negative.

Specifically, your breast cancer needs to be either triple-negative (meaning it doesn't have hormone receptors or HER2 protein) or hormone receptor-positive and HER2-negative, but has stopped responding to hormone therapy combined with CDK4/6 inhibitor treatment.

Also, your breast cancer must have certain genetic changes or a specific test result. These include changes in genes like BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, or your tumour cells must show a 'RAD51-foci low' result. These are important for the study as they might predict how well Lynparza works.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have HER2-negative advanced breast cancer (either triple-negative or hormone-positive that hasn't responded to past treatment)?
  3. Does your cancer have specific gene changes (like BRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutations)?
  4. Or, does your tumour have a 'RAD51-foci low' test result?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, you will take Lynparza tablets, either 150 mg or 100 mg, as instructed by the study team. You will have regular visits to the clinic for check-ups, which will include physical exams and possibly blood tests and scans (like CT or MRI scans) to see how your tumour is responding. These tests will help the doctors measure if your tumour is shrinking or staying the same. The study will also track any side effects you might experience. The total duration of your participation will depend on how you respond to the treatment and the study's monitoring schedule, which can involve regular follow-up for several months or longer.

Riesgos y beneficios potenciales

Taking part in a clinical trial offers the potential benefit of accessing a new treatment like Lynparza before it's widely available, which could help manage your cancer. However, there are also potential risks, including side effects from the medication, which will be carefully monitored. You will be given detailed information about these. It's important to remember that participating is entirely voluntary, and you have the right to withdraw from the study at any time, for any reason, without affecting your standard medical care.

Ubicaciones (1)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    España

Preguntas comunes

What is HER2-negative breast cancer?

HER2-negative breast cancer means your cancer cells do not have a lot of a protein called HER2. This is important because it means certain treatments that target HER2 won't work for you.

What are BRCA1, BRCA2, and other gene mutations?

BRCA1, BRCA2, PALB2, RAD51C, and RAD51D are genes that help repair damaged DNA in your cells. Changes (mutations) in these genes can sometimes increase the risk of certain cancers, including breast cancer, and might make the cancer respond differently to treatments like Lynparza.

What is Lynparza?

Lynparza is a tablet medicine that works by blocking certain proteins in cancer cells, making it harder for them to repair themselves and grow. It's already approved for some cancers and is being tested here for its use in specific breast cancers.

What does 'unresectable locally advanced or metastatic' mean?

This means the breast cancer has either grown too much to be completely removed by surgery (locally advanced) or has spread to other parts of your body (metastatic).

Could this study help me even if my cancer doesn't have these specific gene changes?

This study is specifically designed for people with these particular gene changes or test results because Lynparza is thought to work best in these situations. If you don't have these, your doctor might discuss other treatment options with you instead.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Predicting olaparib sensitivity in patients with unresectabl…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.